Show simple item record

dc.contributor.authorSchmiegelow, K
dc.contributor.authorHeyman, M
dc.contributor.authorGustafsson, G
dc.contributor.authorLausen, B
dc.contributor.authorWesenberg, F
dc.contributor.authorKristinsson, J
dc.contributor.authorVettenranta, K
dc.contributor.authorSchroeder, H
dc.contributor.authorForestier, E
dc.contributor.authorRosthoej, S
dc.date.accessioned2010-05-04T15:00:33Z
dc.date.available2010-05-04T15:00:33Z
dc.date.issued2010-04-01
dc.date.submitted2010-05-04
dc.identifier.citationLeukemia. 2010, 24(4):715-20en
dc.identifier.issn1476-5551
dc.identifier.pmid20130603
dc.identifier.doi10.1038/leu.2009.303
dc.identifier.urihttp://hdl.handle.net/2336/97890
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractDrug doses, blood levels of drug metabolites and myelotoxicity during 6-mercaptopurine/methotrexate (MTX) maintenance therapy were registered for 59 adolescents (>or=10 years) and 176 non-adolescents (<10 years) with B-cell precursor acute lymphoblastic leukemia (ALL) and a white blood cell count (WBC) <50 x 10(9)/l at diagnosis. Event-free survival was lower for adolescents than non-adolescents (pEFS(12y):0.71 vs 0.83, P=0.04). For adolescents staying in remission, the mean WBC during maintenance therapy (mWBC) was related to age (r(S)=0.36, P=0.02), which became nonsignificant for those who relapsed (r(S)=0.05, P=0.9). The best-fit multivariate Cox regression model to predict risk of relapse included mWBC and thiopurine methyltransferase activity, which methylates mercaptopurine and reduces the intracellular availability of cytotoxic 6-thioguanine nucleotides (coefficient: 0.11, P=0.02). The correlation of mWBC to the risk of relapse was more pronounced for adolescents (coefficient=0.65, P=0.003) than for non-adolescents (coefficient=0.42, P=0.04). Adolescents had higher mean neutrophil counts (P=0.002) than non-adolescents, but received nonsignificantly lower mercaptopurine and MTX doses during maintenance therapy. Red blood cell MTX levels were significantly related to the dose of MTX among adolescents who stayed in remission (r(S)=0.38, P=0.02), which was not the case for those who developed a relapse (r(S)=0.15, P=0.60). Thus, compliance to maintenance therapy may influence the risk of relapse for adolescents with ALL.
dc.language.isoenen
dc.publisherNature Publishing Group, Specialist Journalsen
dc.relation.urlhttp://dx.doi.org/10.1038/leu.2009.303en
dc.subject.meshLeukemiaen
dc.subject.meshLymphocyticen
dc.subject.mesh6-Mercaptopurineen
dc.subject.meshAdolescenten
dc.titleThe degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapseen
dc.typeArticleen
dc.contributor.departmentDepartment of Pediatric Oncology, The University Hospital Rigshospitalet, Copenhagen, Denmark. kschmiegelow@rh.dken
dc.identifier.journalLeukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.Ken
html.description.abstractDrug doses, blood levels of drug metabolites and myelotoxicity during 6-mercaptopurine/methotrexate (MTX) maintenance therapy were registered for 59 adolescents (>or=10 years) and 176 non-adolescents (<10 years) with B-cell precursor acute lymphoblastic leukemia (ALL) and a white blood cell count (WBC) <50 x 10(9)/l at diagnosis. Event-free survival was lower for adolescents than non-adolescents (pEFS(12y):0.71 vs 0.83, P=0.04). For adolescents staying in remission, the mean WBC during maintenance therapy (mWBC) was related to age (r(S)=0.36, P=0.02), which became nonsignificant for those who relapsed (r(S)=0.05, P=0.9). The best-fit multivariate Cox regression model to predict risk of relapse included mWBC and thiopurine methyltransferase activity, which methylates mercaptopurine and reduces the intracellular availability of cytotoxic 6-thioguanine nucleotides (coefficient: 0.11, P=0.02). The correlation of mWBC to the risk of relapse was more pronounced for adolescents (coefficient=0.65, P=0.003) than for non-adolescents (coefficient=0.42, P=0.04). Adolescents had higher mean neutrophil counts (P=0.002) than non-adolescents, but received nonsignificantly lower mercaptopurine and MTX doses during maintenance therapy. Red blood cell MTX levels were significantly related to the dose of MTX among adolescents who stayed in remission (r(S)=0.38, P=0.02), which was not the case for those who developed a relapse (r(S)=0.15, P=0.60). Thus, compliance to maintenance therapy may influence the risk of relapse for adolescents with ALL.


This item appears in the following Collection(s)

Show simple item record